Study: T-1249 benefits those with resistance to Fuzeon
BY Advocate.com Editors
September 18 2003 12:00 AM ET
Study data presented Monday at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy show that Roche and Trimeris's second-generation experimental fusion inhibitor, T-1249, can reduce the HIV viral loads of patients who have developed resistance to the companies' first fusion inhibitor, Fuzeon. Data from a Phase I/II study of the experimental drug showed that it was effective in significantly reducing the viral loads of 73% of patients who developed resistance to Fuzeon. No serious drug-related side effects were reported by the study volunteers. "The results from this study of T-1249 demonstrate that fusion inhibitors constitute an expanding class of anti-HIV drugs with the potential to be used sequentially," said Dani Bolognesi, CEO at Trimeris. Next up are Phase II clinical trials, which will begin in 2004.
- WATCH: Gay Couple Assaulted at Dallas BBQ in Chelsea
- WATCH: Jon Stewart's Mic-Drop on Antigay GOP's 'Slim Chances' at White House
- Drag Race's Trixie Mattel: 'I Actually Thought I Would Win'
- WATCH: Janet Mock Gives Oprah 'Ah-Ha' Moments About Gender
- WATCH: Nebraska Woman Is Suing All 'Homosexuals' on Behalf of God
- Meet the Same-Sex Couple Who Made Dodger Stadium Swoon